BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ariosa Diagnostics, Inc. Introduces Y-Chromosome Analysis Test Option


3/18/2013 10:38:06 AM

SAN JOSE, Calif., March 18, 2013 /PRNewswire/ -- Ariosa Diagnostics, maker of the non-invasive Harmony Prenatal Test for risk assessment of common genetic conditions, has announced the expansion of the Harmony Prenatal Test to include the option of Y-chromosome analysis, which can provide information on fetal sex and aneuploidy as early as 10 weeks gestation.

(Logo: http://photos.prnewswire.com/prnh/20130225/SF62999LOGO)

The new "Harmony with Y test" will offer patients and their prenatal care providers with evaluation of the Y-chromosome through which fetal sex can be determined with greater than 99% accuracy. The test also assesses the risk of Y aneuploidy, such as XYY, which is due to an extra copy of chromosome Y. Y aneuploidy is estimated to be present in approximately 1 out of every 1,000 male newborns.

The new Y test follows the recent announcement by Ariosa Diagnostics of expanding the Harmony test to allow for both self and non-self IVF pregnancies. Approximately 5% of all pregnancies, or 300,000, in the United States result from IVF, and the Harmony test allows access to non-invasive prenatal testing for this pregnancy population.

"Our new test offering for Y chromosome analysis provides an option to those women undergoing the Harmony test," said Ken Song, MD, CEO of Ariosa. "XYY is more common than other autosomal trisomies, but has a varying clinical presentation and so proper counseling is needed prior to and following testing."

About Ariosa Diagnostics

Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the Harmony Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The Harmony Prenatal Test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com. Follow us on Twitter @HarmonyPrenatal and on Facebook at Harmony Prenatal for Healthy Pregnancy.

CONTACT:
Jen Bruursema
Ariosa Diagnostics
408-229-7539
jbruursema@ariosadx.com

SOURCE Ariosa Diagnostics



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES